Centiva Capital LP Purchases Shares of 37,387 LifeMD, Inc. (NASDAQ:LFMD)

Centiva Capital LP bought a new position in LifeMD, Inc. (NASDAQ:LFMD) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 37,387 shares of the company’s stock, valued at approximately $196,000. Centiva Capital LP owned about 0.09% of LifeMD as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of LFMD. Quest Partners LLC purchased a new stake in LifeMD in the 2nd quarter worth $31,000. nVerses Capital LLC purchased a new position in LifeMD in the 3rd quarter valued at $46,000. Intech Investment Management LLC purchased a new stake in shares of LifeMD during the third quarter worth $54,000. CWM LLC acquired a new stake in shares of LifeMD in the third quarter valued at about $59,000. Finally, Los Angeles Capital Management LLC purchased a new position in LifeMD during the second quarter worth approximately $88,000. 35.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

LFMD has been the topic of several recent analyst reports. Mizuho began coverage on shares of LifeMD in a report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 target price on shares of LifeMD in a research note on Friday, September 20th. B. Riley began coverage on LifeMD in a report on Friday, August 23rd. They issued a “buy” rating and a $11.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of LifeMD in a research report on Monday, November 11th. Finally, Lake Street Capital assumed coverage on shares of LifeMD in a research note on Tuesday. They set a “buy” rating and a $12.00 target price on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $11.57.

Insider Activity

In related news, CEO Justin Schreiber sold 25,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $6.52, for a total value of $163,000.00. Following the completion of the sale, the chief executive officer now owns 2,728,715 shares in the company, valued at $17,791,221.80. This trade represents a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 15.97% of the company’s stock.

LifeMD Stock Performance

NASDAQ LFMD opened at $5.57 on Friday. The firm has a market cap of $241.25 million, a P/E ratio of -8.70 and a beta of 1.37. LifeMD, Inc. has a 52-week low of $3.99 and a 52-week high of $12.88. The business’s 50-day moving average price is $5.28 and its 200 day moving average price is $5.91. The company has a quick ratio of 0.78, a current ratio of 0.83 and a debt-to-equity ratio of 10.83.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.